Quantcast
Last updated on April 18, 2014 at 12:48 EDT

Latest Drug safety Stories

2013-07-19 08:26:56

ALLEGAN, Mich., July 19, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received tentative approval from the U.S. Food & Drug Administration (FDA) for its abbreviated new drug application (ANDA) for repaglinide tablets, the generic equivalent to Prandin® Tablets (repaglinide tablets). (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ) Prandin® tablets (repaglinide tablets), are indicated as an adjunct to diet and exercise...

2013-07-08 12:29:03

PRINCETON, N.J., July 8, 2013 /PRNewswire/ -- Signum Dermalogix, Inc. ("Dermalogix") a private biopharmaceutical company focused on developing new and innovative dermatological products and services announced that its Investigational New Drug (IND) Application to evaluate SIG990 in rosacea has been cleared by the U.S. Food and Drug Administration (FDA). SIG990 is a safe topical treatment that addresses both erythema and inflammatory lesions and thus would be a significant and...

2013-06-27 23:17:38

No one knows a drug’s side effects like the person taking it and that's why RxISK.org has been created to provide a place where patients can research, report, and share their stories with others. More patients are now reporting side effects to RxISK than to country regulators. Toronto, Canada (PRWEB) June 27, 2013 RxISK.org, the first free independent website for researching and reporting prescription drug side effects, announced today it has had over 2.6 thousand side effects...

2013-06-20 23:23:32

What if Andrew Wakefield was right? New film being produced by Jeff Hays and directed by Bobby Sheehan “Bought” Asks & Answers this Question and Uncovers the Hidden Facts about Vaccinations (PRWEB) June 20, 2013 Jeff Hays today announced that principal photography has begun on the new documentary film — Bought. A new crowd funding campaign at indiegogo.com has an early trailer. Bought is a film dedicated to uncovering, exposing and highlighting the facts all...

2013-06-19 12:27:38

DUBLIN, June 19, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/gdhpt3/otc) has announced the addition of the "OTC Pharmaceuticals and Self-medication in Seven Emerging Markets - Expanded Access, Aging Populations and Increasing Obesity Levels to Drive Future Growth" [http://www.researchandmarkets.com/research/gdhpt3/otc ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Russia's Rapidly...

2013-06-14 23:16:42

Medsight Solutions, a provider of cloud and enterprise-based software for the life sciences industry, will showcase its integrated risk management solution at the DIA 2013 49th Annual Meeting in Boston. Springfield, NJ (PRWEB) June 14, 2013 Medsight Solutions, a provider of cloud and enterprise-based software for the life sciences industry, will showcase its integrated risk management solution at the DIA 2013 49th Annual Meeting in Boston. The advanced software solution, called Medsight...

Obama Administration Drops Bid To Restrict Sales Of Emergency Contraception
2013-06-11 10:50:35

Brett Smith for redOrbit.com - Your Universe Online The Obama administration announced on Monday that it will not dispute a federal judge's order to remove limitations on the purchase of emergency contraception, meaning young girls will soon be able to buy the popular Plan B One-Step pill without a prescription. The Food and Drug Administration (FDA) issued a statement Monday night saying that it would be dropping its appeal of the judge´s ruling. “To comply with the...

2013-06-05 08:28:55

Expedited Development Path will Allow Seamless Integration of AVP-786 into ongoing Clinical Programs ALISO VIEJO, Calif., June 5, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has agreed to an expedited development pathway for their next-generation compound, AVP-786, requiring only a limited pre-clinical package as part of the Investigational New Drug (IND) application. Upon completion of these...

2013-05-31 23:19:03

Dohmen´s BioSoteria Calls for Abstracts for its Seventh Annual Pacific Drug Safety Summit (PDSS); 7th Annual PDSS Safety Summit - Conference Draws Global Biopharmaceutical Drug Safety and Medical Communications Decision-Makers to San Francisco September 19-20, 2013 Emeryville, CA, (PRWEB) May 31, 2013 Dohmen´s BioSoteria Calls for Abstracts for its Seventh Annual Pacific Drug Safety Summit (PDSS) September Conference Draws Global Biopharmaceutical Drug Safety and Medical...

2013-05-23 08:27:06

-- Clinical Trial in Patients with Huntington's Disease Slated to Begin Next Quarter -- SEATTLE, May 23, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an enzyme expressed in areas of the brain linked to a wide range of diseases that affect...